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Supplementary Table A: Baseline characteristics by gender 
Characteristic 
Women 
n=3,283 
Men 
n=10,550 
Age, median years (IQR) 66 (58-73) 63 (55-71) 
Ischaemic HF aetiology, n (%) 1,994 (61%) 7,682 (73%) 
Prior myocardial infarction, n (%) 1,639 (50%) 6,644 63% 
Prior coronary revascularization, n (%) 425 (14%) 2,474 (25%) 
Diabetes Mellitus, n (%) 912 (29%) 2,391 (24%) 
Years with HF diagnosis, median (IQR) 3 (1-6) 3 (1-6) 
LVEF, median % (IQR) 0.28 (0.21-0.34) 0.26 (0.20-0.32) 
NYHA class III/IV, n (%) 2,226 (68%) 6,939 (66%) 
Systolic BP, median mmHg (IQR) 128 (112-140) 121 (110-137) 
Diastolic BP, median mmHg (IQR) 78 (70-83) 77 (70-82) 
Heart rate, median bpm (IQR) 80 (73-88) 79 (72-88) 
Body mass index, median kg/m2 (IQR) 27 (24-31) 27 (24-31) 
Estimated GFR, median mL/min (IQR) 58 (45-70) 65 (53-78) 
Any diuretic therapy, n (%) 2, 863 (87%) 8,947 (85%) 
ACEi or ARB, n (%) 3,089 (94%) 10,014 (95%) 
Aldosterone antagonists, n (%) 286 (9%) 782 (8%) 
Digoxin, n (%) 1,746 (54%) 5,456 (53%) 
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Supplementary Table B: Cause of death by age quartile 
Cause of death Quartile 1 
(youngest) 
Quartile 2 
 
Quartile 3 
 
Quartile 4 
(oldest) 
All ages 
Acute myocardial infarction 5% 5% 6% 6% 6% 
Sudden death 50% 45% 40% 34% 41% 
Heart failure 16% 25% 27% 31% 26% 
Other cardiac 3% 4% 2% 2% 3% 
Stroke 1% 2% 1% 3% 2% 
Other vascular/thrombo-embolic 5% 5% 5% 4% 5% 
Non-cardiovascular 5% 4% 10% 11% 8% 
Unknown 13% 11% 10% 10% 11% 
Total deaths 
412/3,458 
(12%) 
510/3,590 
(14%) 
581/3,327 
(17%) 
687/3,458 
(20%) 
2190/13,833 
(16%) 
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Supplementary Table C: Cause of death by gender 
Cause of death Women Men 
Acute myocardial infarction 6% 5% 
Sudden death 41% 41% 
Heart failure 25% 26% 
Other cardiac 3% 2% 
Stroke 3% 2% 
Other vascular/thrombo-embolic 4% 5% 
Non-cardiovascular 7% 8% 
Unknown 11% 10% 
Total deaths 
462/3,283  
(14%) 
1,728/10,550 
(16%) 
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Supplementary Table D: All-cause mortality and HF-hospitalization according to treatment allocation and age 
Age quartile 
All-cause mortality during median follow-up  
period of 1.3 years (IQR 0.8-1.9) 
Heart failure hospitalization during median follow-up  
period of 1.3 years (IQR 0.8-1.9) 
Placebo Beta-blocker 
Absolute risk 
reduction / Number 
needed to treat 
(NNT) 
Placebo Beta-blocker 
Absolute risk 
reduction / Number 
needed to treat 
(NNT) 
Quartile 1 
(youngest) 
235/1,682 (14.0%) 177/1,776 (10.0%) 4.0% (NNT=25) 277/1,628 (17.0%) 186/1,720 (10.8%) 6.2% (NNT=16) 
Quartile 2 278/1,744 (15.9%) 232/1,846 (12.6%) 3.4% (NNT=29) 330/1,715 (19.2%) 256/1,814 (14.1%) 5.1% (NNT=20) 
Quartile 3 333/1,645 (20.2%) 248/1,682 (14.7%) 5.5% (NNT=18) 337/1,631 (20.7%) 231/1,670 (13.8%) 6.8% (NNT=15) 
Quartile 4 
(oldest) 
376/1,702 (22.1%) 311/1,756 (17.7%) 4.4% (NNT=23) 328/1,702 (19.3%) 287/1,756 (16.3%) 2.9% (NNT=34) 
All ages 
1,222/6,773 
(18.0%) 
968/7,060 
(13.7%) 
4.3% (NNT=23) 
1,272/6,676 
(19.1%) 
960/6,960 
(13.8%) 
5.3% (NNT=19) 
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Supplementary Table E: Sensitivity analyses for all-cause mortality 
Analysis Events/Patients 
Beta-blockers versus placebo Age 
interaction 
p-value 
Gender 
interaction 
p-value Hazard ratio, 95% CI p-value 
Primary adjusted analysis 2,060/13,670 0.70, 0.64 to 0.77 < 0.001 0.10 0.84 
Censor at 365 days 1,202/13,670 0.67, 0.59 to 0.75 < 0.001 0.24 0.40 
Censor at 770 days 1,844/13,670 0.70, 0.63 to 0.76 < 0.001 0.02 0.87 
Exclusion of BEST trial 1,439/11,650 0.64, 0.58 to 0.71 < 0.001 0.02 0.89 
Exclusion of CAPRICORN trial 1,881/12,031 0.69, 0.63 to 0.76 < 0.001 0.23 0.96 
Per protocol a 1,323/11,282 0.67, 0.60 to 0.75 < 0.001 0.22 0.89 
LVEF ≤ 0.35 1,882/11,568 0.70, 0.64 to 0.77 < 0.001 0.12 0.65 
Additional adjustment for diabetes b 1,939/12,964 0.70, 0.64 to 0.77 < 0.001 0.08 0.66 
Additional adjustment for digoxin use at baseline c 2,058/13,378 0.70, 0.64 to 0.77 < 0.001 0.09 0.86 
2 stage c; fixed effects 2,058/13,378 0.71, 0.65 to 0.77 < 0.001 - - 
2 stage c; random effects d 2,058/13,378 0.69, 0.60 to 0.79 < 0.001 - - 
Crude unadjusted analysis 2,119/13,832 0.72, 0.66 to 0.78 < 0.001 0.09 0.81 
Including entire age-range available; adjusted 2,164/14,259 0.72, 0.66 to 0.78 < 0.001 0.57 0.76 
All patients, regardless of rhythm/LVEF/age e 2,984/18,342 0.77, 0.71 to 0.82 <0.001 0.19 0.67 
a Excludes patients that discontinued study therapy.  b Excludes the MDC and CIBIS-I trials.  c Excludes the CHRISTMAS trial.  d p-value for heterogeneity = 0.04, I2 = 48%.  e Post-
hoc adjusted analysis of all patients irrespective of baseline heart rhythm, left-ventricular ejection fraction (LVEF) or age.  All other sensitivity analyses were pre-defined (for details 
on study exclusions and analyses, see Design Paper: Kotecha D, Manzano L, Altman DG, et al.; Syst Rev. 2013;2:7).   
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Supplementary Table F: Beta-blocker discontinuation 
Discontinuation of beta-blockers 
Quartile 1 
(youngest) 
Quartile 2 
 
Quartile 3 
 
Quartile 4 
(oldest) 
All ages 
Women Men Women Men Women Men Women Men Women Men 
   - due to any adverse event 
47  
(14.0%) 
167  
(11.6%) 
51  
(12.9%) 
183  
(12.6%) 
59  
(14.4%) 
186  
(14.6%) 
86  
(15.7%) 
233  
(19.3%) 
243  
(14.4%) 
769  
(14.3%) 
   - due to hypotension* 
2  
(0.9%) 
8  
(0.8%) 
4  
(1.4%) 
14  
(1.4%) 
5  
(1.6%) 
12  
(1.3%) 
3  
(0.7%) 
13  
(1.4%) 
14  
(1.1%) 
47  
(1.2%) 
   - due to bradycardia* 
  
(0.0%) 
3  
(0.3%) 
2  
(0.7%) 
8  
(0.8%) 
3  
(1.0%) 
13  
(1.5%) 
3  
(0.7%) 
33  
(3.5%) 
8  
(0.7%) 
57  
(1.5%) 
   - due to HF exacerbation† 
17  
(5.4%) 
30  
(2.2%) 
13  
(3.5%) 
51  
(3.7%) 
8  
(2.0%) 
53  
(4.4%) 
18  
(3.3%) 
58  
(4.9%) 
56  
(3.5%) 
192  
(3.7%) 
   - due to renal impairment* 
1  
(0.5%) 
4  
(0.4%) 
  
(0.0%) 
2  
(0.2%) 
  
(0.0%) 
5  
(0.6%) 
5  
(1.2%) 
5  
(0.5%) 
6  
(0.5%) 
16  
(0.4%) 
   - due to respiratory dysfunction* 
1  
(0.5%) 
6  
(0.6%) 
3  
(1.1%) 
8  
(0.8%) 
3  
(1.0%) 
10  
(1.1%) 
2  
(0.5%) 
11  
(1.2%) 
9  
(0.7%) 
35  
(0.9%) 
* Data not available for MERIT-HF, CIBIS-I and MDC.  † Partial data only for CIBIS-I and MDC. 
  
8 
Supplementary Table G: Study drug dosage 
Gender 
Mean beta-blocker dosage as a percentage of maximal dose for that study* 
Quartile 1 
(youngest) 
Quartile 2 
 
Quartile 3 
 
Quartile 4 
(oldest) 
All ages 
Women 72% 71% 73% 75% 73% 
Men 76% 74% 71% 70% 73% 
Data not available for BEST and CHRISTMAS; partial data for other trials (n=1,187 for women and n=3,646 for men randomized to beta-blockers).  * Achieved at the interim time 
point for study in patients receiving therapy (median 172 days [IQR 112-198] from randomization). 
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Supplementary Figure A:  Distribution of patients by age and gender 
Frequency histograms for age distribution in men and women (LVEF <0.45 in sinus rhythm; age 40-85). 
 
 
